A simple, sensitive, and specific reversed phase liquid chromatographic method was developed and validated for simultaneous quantification of clopidogrel, its carboxylic acid metabolite, and atorvastatin in human serum. Plasma samples were deproteinized with acetonitrile and ibuprofen was chosen as internal standard. Chromatographic separation was performed on an BDS Hypersil C18 column (250 × 4.6 mm; 5 μm) via gradient elution with mobile phase consisting of 10 mM phosphoric acid (sodium) buffer solution (pH = 2.6 adjusted with 85% orthophosphoric acid) : acetonitrile : methanol with flow rate of 1 mL·min−1. Detection was achieved with PDA detector at 220 nm. The method was validated in terms of linearity, sensitivity, precision, accuracy, limit of quantification, and stability tests. Calibration curves of the analytes were found to be linear in the range of 0.008–2 μg·mL−1 for clopidogrel, 0.01–4 μg·mL−1 for its carboxylic acid metabolite, and 0.005–2.5 μg·mL−1 for atorvastatin. The results of accuracy (as recovery) with ibuprofen as internal standard were in the range of 96–98% for clopidogrel, 94–98% for its carboxylic acid metabolite, and 90–99% for atorvastatin, respectively.

The objective of this study is to formulate and characterize ciprofloxacin-PLGA nanoparticles in laboratory. Ciprofloxacin-PLGA nanoparticles were obtained with Ciprofloxacin and PLGA as raw materials at the room temperature. The optimum set of process parameters were determined using Design of Experiments (DoE) with the factors: PLGA concentration, Ciprofloxacin concentration, Agitation Rate and the responses: Particles Size, Ciprofloxacin Encapsulation. The optimized formulation had 36.83% Ciprofloxacin Encapsulation and 87.58nm Particles Size in the conditions of 10% PLGA Concentration, 24.8 mg Ciprofloxacin Concentration and 1500 Rpm.

There is an increased interest in developing biocomposite implants with high biocompatibility in order to be used as grafts or prostheses in orthopedic surgery. The purpose of the study was to determine the biocompatibility of titanium implants coated with synthesized hydroxyapatite-alendronate composites. The implants were obtained using Matrix Assisted Pulsed Laser Evaporation technique (MAPLE). The hydroxyapatite-alendronate composites were synthesized using the wet precipitation method. Immunofluorescence microscopy showed that composites support mesenchymal stem cells (MSCs) adhesion. Bone cells as well as human MSCs adhere to hydroxyapatite (HA)-based thin films obtained by matrix assisted laser deposition onto titanium. Alendronate doping into the films increased the number of cell-biomaterial focal points as compared to HA only. Thus, the synthesis of hydroxyapatite-alendronate composite (HA-AL) may be considered a viable solution for including the bisphosphonate on the surface of metallic prosthetic components used in orthopedics.